Divi's Laboratories Limited (NSE:DIVISLAB) announced on July 24, 2026, that it will release unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27) on August 1, 2026. Following the results announcement, the company will host an earnings conference call at 14:00 hrs IST the same day to discuss financial performance with analysts and institutional investors.
Key Highlights
- Divi's Laboratories will release Q1 FY27 unaudited financial results on August 1, 2026, as per Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- An earnings conference call is scheduled for August 1, 2026, at 14:00 hrs IST to discuss the company's quarterly financial performance with market participants.
- Investors can join the call through DiamondPass pre-registration or universal dial-in numbers: +91 22 6280 1526 and +91 22 7115 8341.
- A transcript of the conference call will be made available on the company's official website at www.divislabs.com following the call.
- Investors requiring further information can contact the company's Investor Relations team via phone at +91 40 66966352 or mobile at +91 91542 18881.
About the Company
Divi's Laboratories Limited (NSE:DIVISLAB) is a global pharmaceutical company headquartered in Hyderabad, India. The company is engaged in the manufacturing and supply of active pharmaceutical ingredients (APIs), contract research and manufacturing services (CRAMS), and finished pharmaceutical products. Divi's operates manufacturing facilities across multiple geographies and serves pharmaceutical companies, generic manufacturers, and healthcare entities globally. The company is listed on the National Stock Exchange of India and the BSE Limited. Through its diversified portfolio and integrated manufacturing capabilities, Divi's Laboratories serves customers across North America, Europe, India, and emerging markets.
Announcement in Detail
Divi's Laboratories Limited filed a regulatory announcement with the National Stock Exchange of India Limited and BSE Limited on July 24, 2026, pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The announcement communicates the schedule for the company's Q1 FY27 earnings results and conference call. The unaudited financial results for the quarter ended June 30, 2026, will be released on August 1, 2026.
Following the results announcement on the same day, the company will conduct an earnings conference call at 14:00 hrs IST. The call will be hosted by the company's management team to discuss financial performance, operational developments, and respond to questions from analysts and institutional investors. The company has provided two options for participation: pre-registration and direct join via DiamondPass with a confirmation number and security link, or participation through universal dial-in telephone numbers. Participants are advised to dial in approximately five minutes before the scheduled start time, with operator instructions to be provided at that time.
The company has committed to publishing a transcript of the conference call on its website, www.divislabs.com, following the conclusion of the call. Investor Relations contact details have been provided for additional enquiries, including a mobile number +91 91542 18881 and phone number +91 40 66966352. This announcement ensures transparency and compliance with regulatory disclosure norms while providing market participants with structured access to management commentary.
Impact on Investors
Investors will note that the August 1, 2026, results announcement and earnings call provide a scheduled opportunity to review Divi's Laboratories' Q1 FY27 financial performance, including revenue, profitability, margin trends, and operational metrics. The announcement specifies the exact timing and multiple access methods for the earnings call, enabling institutional investors, analysts, equity research professionals, and retail investors to participate in real-time discussion with management. The availability of a post-call transcript on the company website extends access to those unable to join the live call.
The filing demonstrates the company's commitment to timely disclosure and engagement with capital market participants. Shareholders holding Divi's Laboratories equity can use the Q1 FY27 results and management commentary to assess quarterly business performance, market positioning, and financial health. The earnings call represents a structured opportunity to understand management's perspective on operational challenges, market conditions, and strategic priorities during the quarter.
Sector / Market Context
The pharmaceutical sector in India comprises diverse segments including API manufacturing, contract manufacturing, generic drug formulations, and branded pharmaceuticals. Indian API manufacturers serve global markets, particularly the United States, Europe, and emerging economies. Contract research and manufacturing services have grown as global pharmaceutical companies increasingly outsource development and production to specialized partners in India. SEBI-listed pharmaceutical companies routinely announce quarterly results and conduct earnings calls as part of standard investor relations practices and regulatory compliance requirements. Such calls typically provide management insights into industry dynamics, regulatory environment changes, supply chain developments, and company-specific performance drivers relevant to shareholder decision-making.